Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

SCNI

Scinai Immunotherapeutics Ltd ADR

Jun 17 • 12:48PM ET

5.40

Dollar change +1.91
Percentage change 54.73	%

Healthcare • Biotechnology • Israel • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-20.17	Insider Own	2.25%	Shs Outstand	0.46M	Perf Week	88.56%
Market Cap	2.48M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.45M	Perf Month	20.00%
Income	-6.46M	PEG	-	EPS next Q	-	Inst Own	8.83%	Short Float	0.97%	Perf Quarter	8.00%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.10	Perf Half Y	-28.95%
Book/sh	-9.84	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.00M	Perf Year	-61.15%
Cash/sh	10.89	P/C	0.50	EPS next 5Y	-	ROE	-	52W Range	2.23 - 18.70	Perf YTD	-9.30%
Dividend Est.	-	P/FCF	-	EPS past 5Y	46.35%	ROI	-41.42%	52W High	-71.13%	Beta	2.53
Dividend TTM	-	Quick Ratio	3.06	Sales past 5Y	0.00%	Gross Margin	-	52W Low	142.15%	ATR (14)	0.79
Dividend Ex-Date	-	Current Ratio	3.06	EPS Y/Y TTM	65.72%	Oper. Margin	0.00%	RSI (14)	65.89	Volatility	30.26% 17.37%
Employees	31	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	700.00
Option/Short	No / No	LT Debt/Eq	-	EPS Q/Q	-185.60%	Payout	-	Rel Volume	1209.30	Prev Close	3.49
Sales Surprise	-	EPS Surprise	100.21%	Sales Q/Q	-	Earnings	May 15 AMC	Avg Volume	43.69K	Price	5.40
SMA20	52.32%	SMA50	29.22%	SMA200	-11.65%	Trades		Volume	28,122,448	Change	54.73%

Today 07:56AM	Why Is Scinai Immunotherapeutics (SCNI) Stock Up 88% Today? (InvestorPlace) +54.73%
07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jun-13-24 07:00AM	Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity (PR Newswire)
Jun-07-24 07:00AM	Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement (PR Newswire) -28.41%
Jun-03-24 10:52AM	SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q4 2023 (InvestorPlace) -5.33%
04:01PM	Loading…
May-24-24 04:01PM	Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance (PR Newswire) +12.46%
May-15-24 04:01PM	Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update (PR Newswire)
May-06-24 09:21AM	Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal (PR Newswire)
Apr-10-24 07:00AM	Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schn of UMG (PR Newswire)
Apr-08-24 07:00AM	Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services (PR Newswire)
Mar-12-24 08:00AM	Scinai leadership to attend BIO-Europe Spring 2024 (PR Newswire)
Feb-29-24 08:45AM	Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024 (PR Newswire)
Feb-13-24 07:00AM	Scinai Welcomes Liat Halpert as Head of Business Development and Sales (PR Newswire)
Jan-25-24 10:26AM	Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Grlich on Louis-Jeantet Prize (PR Newswire)
Jan-04-24 04:01PM	Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds (PR Newswire)
06:15AM	Loading…
06:15AM	Scinai Immunotherapeutics CEO Issues Letter to Shareholders (PR Newswire)
Dec-29-23 09:21AM	Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds (PR Newswire) -14.93%
Dec-27-23 07:15AM	Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9 (PR Newswire) +9.35%
Dec-20-23 08:05AM	Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors (GlobeNewswire)
Dec-12-23 07:26AM	Scinai Announces Promising Results in a Psoriatic Human Skin Model (PR Newswire) -5.71%
Dec-11-23 08:11AM	Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug (PR Newswire)
Nov-29-23 09:25AM	European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031 (PR Newswire) +7.14%
Nov-20-23 07:30AM	Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule (PR Newswire) -6.35%
Nov-06-23 07:30AM	Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit (GlobeNewswire)
Nov-03-23 04:30PM	Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance (GlobeNewswire)
Oct-31-23 09:00AM	European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai's recent strategic pivot (GlobeNewswire)
08:23AM	Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023 (GlobeNewswire)
Oct-04-23 07:30AM	Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023 (GlobeNewswire) -6.12%
Sep-19-23 04:05PM	Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering (GlobeNewswire)
09:01AM	Loading…
Sep-15-23 09:01AM	Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering (GlobeNewswire) -15.52%
Sep-13-23 04:13PM	Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results (GlobeNewswire)
Sep-11-23 07:30AM	Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston (GlobeNewswire)
Sep-06-23 06:00AM	BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics (GlobeNewswire)
Aug-11-23 09:00AM	BiondVax Reports Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 04:01PM	Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules (GlobeNewswire)
Jul-11-23 08:17AM	IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (GlobeNewswire)
Jun-05-23 07:00AM	BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis (GlobeNewswire) -10.00%
May-30-23 06:00AM	BVXV: Developing anti-IL-17 NanoAb (Zacks Small Cap Research)
May-15-23 04:45PM	BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update (ACCESSWIRE)
Apr-17-23 04:25PM	BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update (GlobeNewswire) +20.11%
Mar-16-23 01:10PM	BiondVax to Present at BIO-Europe Spring (GlobeNewswire) +7.44%
Mar-06-23 01:31PM	IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman (NewMediaWire)
Mar-03-23 02:07PM	IBN Announces Test. Optimize. Scale. Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes (GlobeNewswire)
Feb-02-23 02:15PM	BiondVax Presenting at BIO CEO & Investor Conference (GlobeNewswire)
Jan-23-23 11:50AM	BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate (Benzinga)
06:25AM	BiondVaxs Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study (GlobeNewswire)
Jan-06-23 07:15AM	BiondVaxs Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study (GlobeNewswire) -5.18%
Jan-05-23 07:00AM	BiondVax to Present at Biotech Showcase 2023 (GlobeNewswire) +6.17%
Dec-30-22 07:30AM	BiondVax CEO Issues Letter to Shareholders (GlobeNewswire)
Dec-21-22 11:00AM	Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) (ACCESSWIRE)
Dec-20-22 12:42PM	BiondVax Announces Closing of $8 Million Underwritten Public Offering (GlobeNewswire) -5.09%
Dec-16-22 08:48AM	BiondVax Announces Pricing of $8 Million Underwritten Public Offering (GlobeNewswire) -58.62%
Dec-12-22 07:06AM	BiondVax Regains Nasdaq Compliance (GlobeNewswire)
Dec-08-22 11:05AM	BVXV: Positive Preclinical Results for Inhaled COVID-19 NanoAb (Zacks Small Cap Research)
Dec-06-22 08:30AM	IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd. (GlobeNewswire)
07:30AM	Professor Dr. Matthias Dobbelstein joins BiondVaxs Scientific Advisory Board (GlobeNewswire)
Nov-30-22 09:15AM	BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-29-22 07:00AM	BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy (GlobeNewswire) +7.30%
Nov-21-22 06:00AM	BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco (PR Newswire)
Nov-15-22 08:33AM	BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences (GlobeNewswire)
Nov-10-22 04:00PM	BiondVax Announces Plan to Implement ADS Ratio Change (GlobeNewswire)
Nov-03-22 11:30AM	BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference (PR Newswire)
Nov-02-22 04:30PM	BiondVax provides plan to address Nasdaq compliance (PR Newswire) +7.76%
Oct-18-22 07:55AM	BiondVax to Present at LD Micro Investor Conference in Los Angeles (Newsfile) +9.09%
Oct-11-22 02:00PM	BiondVax to present at LD Micro Investor Conference in Los Angeles (PR Newswire)
Sep-30-22 07:33AM	BiondVax announces financial plans to support its ongoing NanoAb pipeline development (PR Newswire) +10.62%
Sep-22-22 09:05AM	BVXV: Results for Preclinical Inhalation Proof-of-Concept Study in COVID-19 Expected by End of This Year (Zacks Small Cap Research) +11.03%
Sep-20-22 06:15AM	BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19 (PR Newswire)
Sep-08-22 09:13AM	BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-25-22 07:30AM	BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Aug-10-22 08:33AM	BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy (PR Newswire)
Jun-27-22 10:22AM	BVXV: Significant Progress Made in NanoAb Program (Zacks Small Cap Research) +5.41%
Jun-07-22 08:41AM	BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trial (PR Newswire)
Jun-01-22 07:10AM	BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
May-19-22 11:17AM	BiondVax to Present at H.C. Wainwright Global Investment Conference (PR Newswire)
May-12-22 06:30AM	BiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies Program (PR Newswire)
May-09-22 06:00AM	BiondVax to Present at this week's Biomed Israel Conference (PR Newswire) -7.86%
May-02-22 10:15AM	BVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAb Therapies (Zacks Small Cap Research) +8.53%
Apr-05-22 06:49AM	BiondVax to host a Hebrew-language analyst and investor webinar on April 6th (PR Newswire)
Mar-31-22 04:00PM	BiondVax to host analyst and investor webinar on April 4th (PR Newswire) -5.14%
Mar-28-22 07:00AM	BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (PR Newswire)
Mar-24-22 09:45AM	Why Are BiondVax Pharma Shares Gaining Today? (Benzinga) +27.01%
07:05AM	BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapies (PR Newswire)
Mar-14-22 08:31AM	European Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for BiondVax's New Strategy (PR Newswire)
Feb-22-22 08:44AM	BiondVax to Present at Aegis Virtual Conference (PR Newswire)
Feb-15-22 08:31AM	BiondVax to Present at BIO CEO & Investor Conference (PR Newswire)
Feb-10-22 04:30AM	BVXV: Building a Pipeline of VHH Antibody Drug Candidates (Zacks Small Cap Research)
Jan-26-22 07:39AM	BiondVax to Present at Edison Group's Open House Conference (PR Newswire)
Jan-10-22 07:00AM	BiondVax to Present at H.C. Wainwright Bioconnect Virtual Conference (PR Newswire) -9.45%
Jan-03-22 10:15AM	Aegis Capital Corp. Acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) (ACCESSWIRE)
Dec-29-21 04:01PM	BiondVax Announces Successful Closing of $9.8 million Follow-on Underwritten Offering of ADSs Including Exercise of the Over-Allotment (PR Newswire) -6.83%
Dec-27-21 04:01PM	Former CFO of GSK's Global Vaccines Business Mr. Jay Green Joins BiondVax's Board of Directors (PR Newswire) -16.19%
06:45AM	BiondVax Announces Pricing of $9.0 million Follow-on Underwritten Offering of American Depositary Shares (PR Newswire)
Dec-23-21 08:01PM	BiondVax Announces Proposed Underwritten Public Offering of American Depositary Shares (PR Newswire)
Dec-22-21 11:29AM	BVXV Stock Alert: The Covid-19 Antibody News Sending BiondVax Pharma Soaring (InvestorPlace) +97.30%
09:09AM	BiondVax Shares More Than Double On Deal For Nanosized Covid-19 Antibody Therapy (Investing.com)
09:00AM	BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody (Benzinga)
07:07AM	BiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany (PR Newswire)
Nov-30-21 07:05AM	BiondVax announces Third Quarter 2021 Financial Results and Provides Business Update (PR Newswire) -5.82%

Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCNI

Scinai Immunotherapeutics Ltd ADR

Upgrade your FINVIZ experience